Latest News and Press Releases

Study is evaluating ALRN-6924 to protect against chemotherapy-induced bone marrow toxicities in patients with p53-mutated small cell lung cancer (SCLC) treated with topotecanPreviously reported...

WATERTOWN, Mass., May 30, 2019 (GLOBE NEWSWIRE) -- Aileron Therapeutics (NASDAQ: ALRN), the clinical-stage leader in the field of stabilized cell-permeating peptides to treat cancer and other...

Manuel Aivado, MD, PhD, promoted to President and Chief Executive OfficerVojislav Vukovic, MD, appointed Senior Vice President, Chief Medical Officer, and Allen Annis, PhD, promoted to Senior Vice...

WATERTOWN, Mass., Sept. 06, 2018 (GLOBE NEWSWIRE) -- Aileron Therapeutics (NASDAQ: ALRN), the clinical-stage leader in the field of stapled peptide therapeutics for cancers and other diseases, today...

Preclinical in-vivo ALRN-6924 combination data with CDK4/6 inhibitors, PD-1/-L1 inhibitors, or paclitaxel (formulated as Abraxane or Taxol) all show promise in breast cancer and other cancer models...

CAMBRIDGE, Mass., Aug. 02, 2018 (GLOBE NEWSWIRE) -- Aileron Therapeutics (Nasdaq:ALRN), the leader in the field of stapled peptide therapeutics for cancers and other diseases, today announced that...

CAMBRIDGE, Mass., July 31, 2018 (GLOBE NEWSWIRE) -- Aileron Therapeutics (Nasdaq:ALRN), the leader in the field of stapled peptide therapeutics for cancers and other diseases, today announced that...

CAMBRIDGE, Mass., May 29, 2018 (GLOBE NEWSWIRE) -- Aileron Therapeutics (Nasdaq:ALRN), the leader in the field of stapled peptide therapeutics for cancers and other diseases, today announced that...

CAMBRIDGE, Mass., May 22, 2018 (GLOBE NEWSWIRE) -- Aileron Therapeutics (Nasdaq:ALRN), the leader in the field of stapled peptide therapeutics for cancers and other diseases, today announced the...

CAMBRIDGE, Mass., May 15, 2018 (GLOBE NEWSWIRE) -- Aileron Therapeutics (Nasdaq:ALRN), the clinical-stage leader in the field of stapled peptide therapeutics for cancers and other diseases, today...